TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions.

Lightweight, high-precision AI model effectively overcomes two major barriers to AI deployment in bladder cancer care: Low detection rates for difficult-to-identify lesions. Prohibitive computational ...

Papillary disease is estimated to be approximately 6-10 times more common than bladder cancer CIS, representing a large patient population that may benefit from ANKTIVA plus BCG. 1 About the QUILT ...

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

In patients with CIS [carcinoma in situ], the probability ... Several studies have shown increased PD-1 expression in bladder tumors after BCG treatment, supporting combination treatment with ...